Ultragenyx Pharmaceutical (RARE) Return on Equity (2017 - 2025)
Historic Return on Equity for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to 7.24%.
- Ultragenyx Pharmaceutical's Return on Equity fell 58100.0% to 7.24% in Q3 2025 from the same period last year, while for Sep 2025 it was 7.24%, marking a year-over-year decrease of 58100.0%. This contributed to the annual value of 2.15% for FY2024, which is 2200.0% down from last year.
- As of Q3 2025, Ultragenyx Pharmaceutical's Return on Equity stood at 7.24%, which was down 58100.0% from 3.62% recorded in Q2 2025.
- Ultragenyx Pharmaceutical's 5-year Return on Equity high stood at 0.19% for Q1 2021, and its period low was 7.95% during Q3 2023.
- Its 5-year average for Return on Equity is 2.42%, with a median of 1.9% in 2024.
- Per our database at Business Quant, Ultragenyx Pharmaceutical's Return on Equity crashed by -67600bps in 2023 and then skyrocketed by 65100bps in 2024.
- Quarter analysis of 5 years shows Ultragenyx Pharmaceutical's Return on Equity stood at 0.49% in 2021, then tumbled by -252bps to 1.73% in 2022, then tumbled by -128bps to 3.95% in 2023, then surged by 52bps to 1.9% in 2024, then plummeted by -282bps to 7.24% in 2025.
- Its Return on Equity stands at 7.24% for Q3 2025, versus 3.62% for Q2 2025 and 2.76% for Q1 2025.